Complete remission after sintilimab combined with chemoradiotherapy in double primary head and neck carcinoma
Author Information
Author(s): Lu Xiameng, Tan Bibo, Yang Liuting, Huang Suning
Primary Institution: Guangxi Medical University Cancer Hospital
Hypothesis
Can a combination of chemoradiotherapy and immune checkpoint inhibitors effectively treat double primary head and neck squamous cell carcinoma?
Conclusion
The patient achieved complete remission and maintained a good quality of life after treatment.
Supporting Evidence
- The patient achieved complete remission in both tumors after treatment.
- Progression-free survival was nearly 3 years with minimal side effects.
- The treatment regimen included chemoradiotherapy and an immune checkpoint inhibitor.
Takeaway
A 70-year-old man with two types of throat cancer was treated with a special combination of therapies and got completely better.
Methodology
The patient received induction chemotherapy followed by concurrent chemoradiotherapy and immunotherapy.
Potential Biases
Potential for immune-related adverse events requiring careful monitoring.
Limitations
The treatment approach lacks randomized controlled trials and long-term follow-up data.
Participant Demographics
70-year-old male patient with a history of smoking and alcohol consumption.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website